Uncategorized
Novartis challenges UK Avastin use in eye disease
ZURICH/LONDON (Reuters) - Swiss drugmaker Novartis is challenging the use of a cheap alternative to
its eye drug Lucentis in parts of Britain, sparking a row over cost versus safety in treating a common cause of
blindness.